Gadopentetate dimeglumine, which is a gadolinium coordination compound, consists of gadolinium and a chelating agent called diethylenetriaminepentaacetic acid (DTPA). Its primary purpose is to serve as a contrast agent for magnetic resonance imaging (MRI) in diagnostic procedures. This contrast agent utilizes gadolinium, a rare earth element known for its paramagnetic properties. It is specifically indicated for enhancing contrast in cranial and spinal MRI examinations for both adults and children. Its use helps in identifying lesions associated with abnormal vascularity or those suspected of affecting the blood-brain barrier.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Gadopentetate Dimeglumine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.